Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know [Yahoo! Finance]
Century Therapeutics (NASDAQ:IPSC) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes [Yahoo! Finance]
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
Century Therapeutics (NASDAQ:IPSC) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.